Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:vaccine_technology
|
| gptkbp:advantage |
induces strong immune response
low pre-existing immunity in humans non-replicating vector |
| gptkbp:developedBy |
gptkb:University_of_Oxford
|
| gptkbp:introducedIn |
2012
|
| gptkbp:notableProduct |
gptkb:AZD1222
|
| gptkbp:platform |
gptkb:virus
|
| gptkbp:relatedTo |
gptkb:Sarah_Gilbert
gptkb:AstraZeneca gptkb:Jenner_Institute |
| gptkbp:usedFor |
gptkb:vaccine
gptkb:influenza vaccine development MERS vaccine |
| gptkbp:usedIn |
gptkb:Oxford–AstraZeneca_COVID-19_vaccine
|
| gptkbp:vectorFor |
gptkb:chimpanzee_adenovirus
|
| gptkbp:bfsParent |
gptkb:Vaccitech
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
ChAdOx1 technology
|